Home' Australian Pharmacist : Australian Pharmacist January 2013 Contents Australian Pharmacist January 2013 I ©Pharmaceutical Society of Australia Ltd. 77
BUSINESS AND INDUSTRY NEWS
Swisse goes global
Australian wellness brand Swisse will use
the famous G'day USA black tie ball in
Hollywood to formally launch into its first
international market -- the United States on
Swisse will join Qantas as major sponsors
of the annual Aussie celebration in Los
Angeles that promotes trade and tourism in
the lucrative American market. This year the
event, in its 10th year, will be held at the JW
Marriott in Los Angeles, three weeks before
Swisse products hit shelves at Walgreens
stores across the US.
Starting on 1 February 15 of the most
popular Swisse products in Australia, will
also be sold in the USA, including Men's and
Women's Ultivites, Krill Oil, Hair, Skin Nails,
Liver Detox and Appetite Suppressant.
Swisse Global Ambassador Nicole Kidman
will walk the red carpet at G'day USA and
will be involved in a special presentation on
The company has also signed deals with
other major American retailers which will be
unveiled in coming weeks.
Swisse had planned to launch in America
with just vitamins and supplements, however,
retailers have expressed interest in the Swisse
body skin care range and the Swisse Active
sports nutrition range of protein bars, protein
powders and amino acids.
The company will base its USA head office
in Chicago, and key team members from
Australia will relocate to the United States.
However, the global headquarters will
remain in Melbourne. It has also locked in
other international deals for distribution as
the company goes global this year.
Swisse CEO Radek Sali said, 'We set an
ambitious target for our international
business to be up and running in early
2013 and the Swisse team has delivered on
'Our Australian success is recognised as
a global opportunity, as validated by
the huge support shown by retailers
world-wide to range our products across all
stores,' he said.
A top CEO
Swisse CEO, Radek Sali, was named as the
Health and Pharmaceutical Executive of
2012 at the CEO Magazine annual awards
in November. He was also the runner up for
CEO of the Year. The award organisers said
Mr Sali was one of Australia's youngest CEOs
and held the position in a company that
can justifiably claim to be one of Australia's
business success stories.
Since becoming CEO in 2009, the company's
annual sales have grown from $15 million to
$182.6m this financial year.
Interim authorisation granted
The Australian Competition and Consumer
Commission has granted interim
authorisation to eRx Script Exchange to allow
it to enter into a contract with MediSecure
to facilitate interoperability between
the parties' electronic pharmaceutical
prescription exchange systems.
Prescription exchange services enable
doctors to lodge an electronic prescription
for a patient, which the patient can
then have downloaded directly by any
eRx and MediSecure are currently the
only two parties operating prescription
exchange services in Australia, but their two
systems do not currently 'talk' to each other.
This is preventing greater use of electronic
ACCC Chairman Rod Sims said: 'Allowing the
parties to implement the agreement under
an interim authorisation is likely to increase
the use of electronic prescriptions. This will
result in cost savings and a reduction in
prescription transcription errors.'
The Commonwealth Department of Health
and Aging has provided funding to ensure
that electronic prescriptions can be accessed
by all pharmacies, irrespective of the
prescription exchange service with which
it was originally lodged.
Authorisation provides immunity from
court action for conduct that might
otherwise raise concerns under the
competition provisions of the Competition
and Consumer Act 2010. Broadly, the ACCC
may grant an authorisation when it is
satisfied that the public benefit from the
conduct outweighs any public detriment.
Interim authorisation allows the parties
to engage in the conduct before the
ACCC considers the substantive merits of
Chemmart proactive in bowel
Almost 200 Chemmart customers have
been alerted to abnormal bowel cancer
screening test results as a result of the its
Bowel Screen Program.
During the past 12 months, Chemmart
Pharmacy customers have undertaken
approximately 2,000 Bowel Screen
Australia tests which resulted in the
detection of 10 cases of bowel cancer.
The tests also alerted almost 190 people to
polyps and other diseases of the bowel such
as Crohn's or Colitis -- which can put people
at high risk of developing bowel cancer.
Katie Fala, Chemmart Health Services
Manager said deaths from bowel cancer
are still very high in Australia with the
disease claiming more than 4,000 lives
'We also know that when bowel cancer
is found at the earliest stage, there is an
excellent chance of survival - so early
diagnosis is critical.'
Bowel cancer is the second most common
cancer in Australia and has a 90% chance of
being cured if it's discovered early enough.1
A new study has revealed that up to 20%
of adults with bowel cancer symptoms,
have not consulted their doctor.1
'These findings show there is more work
to be done to raise awareness of bowel
cancer at the community level, and
highlights the important role pharmacies
can play in early detection,' Ms Fala said.
1. Bowel Cancer Australia (2012) refer www.bowelcanceraustralia.org
Swisse Global Ambassador Nicoke Kidman.
Links Archive Australian Pharmacist December 2012 February 2013 Navigation Previous Page Next Page